Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the prostate cancer prevention trial

Douglas K. Price; Cindy H. Chau; Cathee Till; Phyllis J. Goodman; Caitlin E. Baum; Sandy B. Ockers; Bevin C. English; Lori Minasian; Howard L. Parnes; Ann W. Hsing; Juergen K.V. Reichardt; Ashraful Hoque; Catherine M. Tangen; Alan R. Kristal; Ian M. Thompson; William D. Figg

doi:10.1016/j.juro.2010.08.005

Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the prostate cancer prevention trial

Douglas K. Price, Cindy H. Chau, Cathee Till, Phyllis J. Goodman, Caitlin E. Baum, Sandy B. Ockers, Bevin C. English, Lori Minasian, Howard L. Parnes, Ann W. Hsing, Juergen K.V. Reichardt, Ashraful Hoque, Catherine M. Tangen, Alan R. Kristal, Ian M. Thompson, William D. Figg

Clinical Cancer Prevention

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Purpose We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer. Materials and Methods This is a nested case-control study of 1,159 cases and 1,353 controls from the Prostate Cancer Prevention Trial, a randomized, placebo controlled trial testing whether the 5α-reductase inhibitor finasteride could decrease the 7-year prevalence of prostate cancer. During the course of the trial men underwent annual digital rectal examination and prostate specific antigen measurement. Prostate biopsy was recommended in all men with abnormal digital rectal examination or finasteride adjusted prostate specific antigen greater than 4.0 ng/ml. Cases were drawn from men with biopsy determined prostate cancer identified by for cause or end of study biopsy. Controls were selected from men who completed the end of study biopsy. Results Mean CAG repeat length did not differ between cases and controls. The frequency distribution of cases and controls for the AR CAG repeat length was similar. There were no significant associations of CAG repeat length with prostate cancer risk when stratified by treatment arm (finasteride or placebo), or when combined. There was also no significant association between CAG repeat length and the risk of low or high grade prostate cancer. Conclusions There is no association of AR CAG repeat length with prostate cancer risk. Knowledge of AR CAG repeat length provides no clinically useful information to predict prostate cancer risk.

Original language	English (US)
Pages (from-to)	2297-2302
Number of pages	6
Journal	Journal of Urology
Volume	184
Issue number	6
DOIs	https://doi.org/10.1016/j.juro.2010.08.005
State	Published - Dec 2010

Keywords

African continental ancestry group
European continental ancestry group
Prostate
Prostatic neoplasms
Receptors androgen

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.juro.2010.08.005

Cite this

Price, D. K., Chau, C. H., Till, C., Goodman, P. J., Baum, C. E., Ockers, S. B., English, B. C., Minasian, L., Parnes, H. L., Hsing, A. W., Reichardt, J. K. V., Hoque, A., Tangen, C. M., Kristal, A. R., Thompson, I. M., & Figg, W. D. (2010). Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the prostate cancer prevention trial. Journal of Urology, 184(6), 2297-2302. https://doi.org/10.1016/j.juro.2010.08.005

Price, DK, Chau, CH, Till, C, Goodman, PJ, Baum, CE, Ockers, SB, English, BC, Minasian, L, Parnes, HL, Hsing, AW, Reichardt, JKV, Hoque, A, Tangen, CM, Kristal, AR, Thompson, IM & Figg, WD 2010, 'Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the prostate cancer prevention trial', Journal of Urology, vol. 184, no. 6, pp. 2297-2302. https://doi.org/10.1016/j.juro.2010.08.005

@article{390e6015ec384eb7b46776f8ca645be5,

title = "Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the prostate cancer prevention trial",

abstract = "Purpose We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer. Materials and Methods This is a nested case-control study of 1,159 cases and 1,353 controls from the Prostate Cancer Prevention Trial, a randomized, placebo controlled trial testing whether the 5α-reductase inhibitor finasteride could decrease the 7-year prevalence of prostate cancer. During the course of the trial men underwent annual digital rectal examination and prostate specific antigen measurement. Prostate biopsy was recommended in all men with abnormal digital rectal examination or finasteride adjusted prostate specific antigen greater than 4.0 ng/ml. Cases were drawn from men with biopsy determined prostate cancer identified by for cause or end of study biopsy. Controls were selected from men who completed the end of study biopsy. Results Mean CAG repeat length did not differ between cases and controls. The frequency distribution of cases and controls for the AR CAG repeat length was similar. There were no significant associations of CAG repeat length with prostate cancer risk when stratified by treatment arm (finasteride or placebo), or when combined. There was also no significant association between CAG repeat length and the risk of low or high grade prostate cancer. Conclusions There is no association of AR CAG repeat length with prostate cancer risk. Knowledge of AR CAG repeat length provides no clinically useful information to predict prostate cancer risk.",

keywords = "African continental ancestry group, European continental ancestry group, Prostate, Prostatic neoplasms, Receptors androgen",

author = "Price, {Douglas K.} and Chau, {Cindy H.} and Cathee Till and Goodman, {Phyllis J.} and Baum, {Caitlin E.} and Ockers, {Sandy B.} and English, {Bevin C.} and Lori Minasian and Parnes, {Howard L.} and Hsing, {Ann W.} and Reichardt, {Juergen K.V.} and Ashraful Hoque and Tangen, {Catherine M.} and Kristal, {Alan R.} and Thompson, {Ian M.} and Figg, {William D.}",

note = "Funding Information: Supported by the National Cancer Institute , National Institutes of Health Intramural Research Program , American College of Clinical Pharmacy/Research Institute , National Institutes of Health National Center for Minority Health and Health Disparity , and National Cancer Institute Prostate Cancer Prevention Trial PO1 Grant CA108964 . ",

year = "2010",

month = dec,

doi = "10.1016/j.juro.2010.08.005",

language = "English (US)",

volume = "184",

pages = "2297--2302",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Androgen receptor CAG repeat length and association with prostate cancer risk

T2 - Results from the prostate cancer prevention trial

AU - Price, Douglas K.

AU - Chau, Cindy H.

AU - Till, Cathee

AU - Goodman, Phyllis J.

AU - Baum, Caitlin E.

AU - Ockers, Sandy B.

AU - English, Bevin C.

AU - Minasian, Lori

AU - Parnes, Howard L.

AU - Hsing, Ann W.

AU - Reichardt, Juergen K.V.

AU - Hoque, Ashraful

AU - Tangen, Catherine M.

AU - Kristal, Alan R.

AU - Thompson, Ian M.

AU - Figg, William D.

N1 - Funding Information: Supported by the National Cancer Institute , National Institutes of Health Intramural Research Program , American College of Clinical Pharmacy/Research Institute , National Institutes of Health National Center for Minority Health and Health Disparity , and National Cancer Institute Prostate Cancer Prevention Trial PO1 Grant CA108964 .

PY - 2010/12

Y1 - 2010/12

N2 - Purpose We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer. Materials and Methods This is a nested case-control study of 1,159 cases and 1,353 controls from the Prostate Cancer Prevention Trial, a randomized, placebo controlled trial testing whether the 5α-reductase inhibitor finasteride could decrease the 7-year prevalence of prostate cancer. During the course of the trial men underwent annual digital rectal examination and prostate specific antigen measurement. Prostate biopsy was recommended in all men with abnormal digital rectal examination or finasteride adjusted prostate specific antigen greater than 4.0 ng/ml. Cases were drawn from men with biopsy determined prostate cancer identified by for cause or end of study biopsy. Controls were selected from men who completed the end of study biopsy. Results Mean CAG repeat length did not differ between cases and controls. The frequency distribution of cases and controls for the AR CAG repeat length was similar. There were no significant associations of CAG repeat length with prostate cancer risk when stratified by treatment arm (finasteride or placebo), or when combined. There was also no significant association between CAG repeat length and the risk of low or high grade prostate cancer. Conclusions There is no association of AR CAG repeat length with prostate cancer risk. Knowledge of AR CAG repeat length provides no clinically useful information to predict prostate cancer risk.

AB - Purpose We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer. Materials and Methods This is a nested case-control study of 1,159 cases and 1,353 controls from the Prostate Cancer Prevention Trial, a randomized, placebo controlled trial testing whether the 5α-reductase inhibitor finasteride could decrease the 7-year prevalence of prostate cancer. During the course of the trial men underwent annual digital rectal examination and prostate specific antigen measurement. Prostate biopsy was recommended in all men with abnormal digital rectal examination or finasteride adjusted prostate specific antigen greater than 4.0 ng/ml. Cases were drawn from men with biopsy determined prostate cancer identified by for cause or end of study biopsy. Controls were selected from men who completed the end of study biopsy. Results Mean CAG repeat length did not differ between cases and controls. The frequency distribution of cases and controls for the AR CAG repeat length was similar. There were no significant associations of CAG repeat length with prostate cancer risk when stratified by treatment arm (finasteride or placebo), or when combined. There was also no significant association between CAG repeat length and the risk of low or high grade prostate cancer. Conclusions There is no association of AR CAG repeat length with prostate cancer risk. Knowledge of AR CAG repeat length provides no clinically useful information to predict prostate cancer risk.

KW - African continental ancestry group

KW - European continental ancestry group

KW - Prostate

KW - Prostatic neoplasms

KW - Receptors androgen

UR - http://www.scopus.com/inward/record.url?scp=78349310918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349310918&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2010.08.005

DO - 10.1016/j.juro.2010.08.005

M3 - Article

C2 - 20952028

AN - SCOPUS:78349310918

SN - 0022-5347

VL - 184

SP - 2297

EP - 2302

JO - Journal of Urology

JF - Journal of Urology

IS - 6

ER -

Androgen receptor CAG repeat length and association with prostate cancer risk: Results from the prostate cancer prevention trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this